Zoetis Inc. (NYSE:ZTS) Shares Bought by Isthmus Partners LLC

Isthmus Partners LLC grew its stake in shares of Zoetis Inc. (NYSE:ZTS) by 1.1% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 68,648 shares of the company’s stock after purchasing an additional 760 shares during the quarter. Zoetis makes up about 1.6% of Isthmus Partners LLC’s holdings, making the stock its 26th biggest position. Isthmus Partners LLC’s holdings in Zoetis were worth $13,412,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in ZTS. Darwin Wealth Management LLC acquired a new stake in Zoetis during the third quarter worth approximately $31,000. First Personal Financial Services acquired a new stake in Zoetis during the third quarter worth approximately $33,000. Capital Performance Advisors LLP acquired a new stake in Zoetis during the third quarter worth approximately $33,000. Quarry LP raised its holdings in Zoetis by 273.2% during the second quarter. Quarry LP now owns 209 shares of the company’s stock worth $36,000 after purchasing an additional 153 shares in the last quarter. Finally, LRI Investments LLC acquired a new stake in Zoetis during the first quarter worth approximately $43,000. Institutional investors and hedge funds own 92.80% of the company’s stock.

Zoetis Stock Performance

NYSE:ZTS opened at $176.74 on Friday. The firm’s fifty day moving average price is $184.18 and its 200 day moving average price is $180.78. Zoetis Inc. has a 1-year low of $144.80 and a 1-year high of $201.92. The company has a debt-to-equity ratio of 1.26, a current ratio of 3.69 and a quick ratio of 2.27. The firm has a market cap of $79.74 billion, a price-to-earnings ratio of 33.22, a price-to-earnings-growth ratio of 2.71 and a beta of 0.90.

Zoetis (NYSE:ZTS) last posted its quarterly earnings data on Monday, November 4th. The company reported $1.58 earnings per share for the quarter, beating analysts’ consensus estimates of $1.46 by $0.12. Zoetis had a net margin of 26.55% and a return on equity of 51.98%. The firm had revenue of $2.40 billion for the quarter, compared to analyst estimates of $2.29 billion. During the same period last year, the firm posted $1.36 EPS. Zoetis’s quarterly revenue was up 11.6% on a year-over-year basis. On average, sell-side analysts expect that Zoetis Inc. will post 5.9 EPS for the current year.

Zoetis Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, December 3rd. Shareholders of record on Thursday, October 31st will be issued a $0.432 dividend. This represents a $1.73 dividend on an annualized basis and a yield of 0.98%. The ex-dividend date is Thursday, October 31st. Zoetis’s dividend payout ratio (DPR) is currently 32.52%.

Analyst Ratings Changes

ZTS has been the topic of a number of research analyst reports. Stifel Nicolaus raised their price objective on shares of Zoetis from $200.00 to $210.00 and gave the stock a “buy” rating in a report on Wednesday, September 18th. BTIG Research raised their target price on shares of Zoetis from $220.00 to $225.00 and gave the stock a “buy” rating in a research report on Monday, August 12th. Piper Sandler raised their target price on shares of Zoetis from $195.00 to $210.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 14th. JPMorgan Chase & Co. raised their target price on shares of Zoetis from $225.00 to $230.00 and gave the stock an “overweight” rating in a research report on Friday, October 11th. Finally, Argus upgraded shares of Zoetis to a “strong-buy” rating in a research report on Friday, August 9th. Ten analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, Zoetis presently has a consensus rating of “Buy” and a consensus target price of $221.44.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.